// App-Quantinova.ai

P963 : EVOLUTION OF TREATMENT PATTERNS AND OVERALL SURVIVAL IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA RECEIVING A SECOND LINE OF THERAPY BETWEEN 2012 AND 2020: ANALYSIS OF THE PREAMBLE COHORT

Researchers

Presenter

  • David Kuter

Principal Investigators

  • Hartmut Goldschmidt

  • David Cella

  • Maria Teresa Petrucci

  • Philippe Moreau

  • Brian Durie

  • Ariadna Juarez-Garcia

  • Jin Gu

  • Sujith Dhanasiri

  • Thomas Marshall

  • Jenny Wang

  • Laure Lacoin

  • Karthik Ramasamy

  • Ravi Vij

Medical Centers

  • Siteman Cancer Center, Washington University in St. Louis,St. Louis, MO,Vereinigte Staaten

  • Cedars Sinai Cancer Center,Los Angeles, CA,Estados Uni

  • Bristol-Myers Squibb,Boudry,Швейцария

  • University Hospital Heidelberg, Internal Medicine V and National Center for Tumor Diseases (NCT),Heidelberg,Germania

  • Department of Cellular Pathology, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom

  • Service d'hématologie cli

  • Bristol Myers Squibb,Princeton, NJ,Estados Unidos

  • Bristol Myers Squibbs,Princeton,Vereinigte Staaten

  • Department of Cellular Biotechnologies and Hematology, Sapienza University of Rome, Rome, Italy

  • Siteman Cancer Center, Washington University in St. Louis,St. Louis, MO,Vereinigte Staaten

  • University Hospital Heidelberg, Internal Medi

  • Cedars Sinai Cancer Center,Los Angeles, CA,Vereinigte Staaten

  • Siteman Cancer Center, Washington University in St. Louis,St. Louis, MO,Vereinigte Staaten

  • Hematology Division, Massachusetts General Hospital,Boston, MA,États-unis

  • Service d'hématologie clinique, CHU Hôtel Dieu,Nantes,France

  • Department of Cellul

  • Rheumatology, Massachusetts General Hospital, Boston, United States

  • Bristol Myers Squibb,Princeton, NJ,Estados Unidos

  • Bri

  • Department of Haematology,Oxford University Hospitals NHS Foundation Trust,Oxford,Royaume-uni

  • Cedars Sinai Cancer Center,Los Angeles, CA,Vereinigte Staaten

  • Department of Medical Social Sciences and Robert H. Lurie Comprehensive Cancer Center, Northwestern University,Chicago, IL,Vereinigte Staaten

  • Bristol Myers Squibbs,Princeton,Vereinigte Staaten

  • Siteman Cancer Center, Washington University, Saint Louis, MO

  • Cedars Sinai Cancer Center,Los Angeles, CA,United States

  • Epi-Fit,Bordeaux,Франция

  • Department of Clinical Haematology,Oxford University Hospitals NHS Foundation Trust,Oxford,Vereinigtes Königreich

  • University Hospital Heidelberg, Internal Medicine V and National Center for Tumor Diseases (NCT),Heidelberg,Germania

  • Bristol Myers Squibb,Princeton, NJ,Estados Unidos

  • Department of Cellular Biotechnologies and Hematology, Sapienza University of Rome, Rome, Italy

  • Department of Cellular Biotechnologies and Hematology, Sapienza University of Rome, Rome, Italy

  • Service d'hématologie clinique, CHU Hôtel Dieu,Nantes,France

  • Hematology Division, Massachusetts General Hospital,Boston, MA,États-unis

  • Cedars Sinai Cancer Center,Los Angeles, CA,Estados Uni

  • Cedars Sinai Cancer Center,Los Angeles, CA,Estados Uni

  • Department of Cellular Biotechnologies and Hematology, Sapienza University of Rome, Rome, Italy

  • Department of Haematology,Oxford University Hospitals NHS Foundation Trust,Oxford,Royaume-uni

  • Cedars Sinai Cancer Center,Los Angeles, CA,Estados Uni

  • Bristol-Myers Squibb,Boudry,Zwitserland

  • Hematology Divis

  • Department of Medical Social Sciences and Robert H. Lurie Comprehensive Cancer Center, Northwestern University,Chicago, IL,Vereinigte Staaten

  • Hematology Division, Massachusetts General Hospital,Boston, MA,États-unis

  • Hematology Division, Massachusetts General Hospital,Boston, MA,Estados Unidos

  • Service d'hématologie clinique, CHU Hôtel Dieu,Nantes,France

  • Depart

  • Bristol Myers Squibb, Princeton, New Jersey, United States

  • Department of Medical Social Sciences and Robert H. Lurie Comprehensive Cancer Center, Northwestern University,Chicago, IL,Vereinigte Staaten

  • Bristol-Myers Squibb Company, Boudry, Switzerland

  • University Hospital Heidelberg, Internal Medicine V and National Center for Tumor Diseases (NCT),Heidelberg,Germania

  • Service d'hématologie clinique, CHU Hôtel Dieu,Nantes,France

Locations

  • United States

  • South Africa

  • Italy

  • France

  • Switzerland

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Multiple Myeloma

Biomarkers

  • N/A

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Cohort

Phase

  • N/A

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved